CA Patent

CA3020592A1 — Novel crystalline form of lumacaftor

Assigned to Apotex Inc · Expires 2019-04-17 · 7y expired

What this patent protects

The present invention provides a novel crystalline form of Lumacaftor, specifically Lumacaftor Form APO-1, a co-crystal of Lumacaftor and nicotinamide, compositions and processes for the preparation thereof, and the use of this crystalline form in the treatment of cystic fibrosis…

USPTO Abstract

The present invention provides a novel crystalline form of Lumacaftor, specifically Lumacaftor Form APO-1, a co-crystal of Lumacaftor and nicotinamide, compositions and processes for the preparation thereof, and the use of this crystalline form in the treatment of cystic fibrosis.

Drugs covered by this patent

Patent Metadata

Patent number
CA3020592A1
Jurisdiction
CA
Classification
—
Expires
2019-04-17
Drug substance claim
No
Drug product claim
No
Assignee
Apotex Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.